Celcuity Taps Pharma Veteran Charles Romp to Bolster Commercial Launch of Gedatolisib
Celcuity appointed Charles 'Chip' R. Romp, former Seagen commercial EVP, to its Board, bringing over 25 years of oncology sales and commercial leadership. His track record commercializing ADCETRIS, PADCEV, TUKYSA and TIVDAK is expected to support Celcuity’s planned gedatolisib approval and launch later this year.
1. Board Appointment
On February 12, 2026, Celcuity named Charles 'Chip' R. Romp to its Board of Directors to enhance its commercial expertise as the company advances its pipeline.
2. Romp's Industry Experience
Romp brings over 25 years of pharmaceutical industry experience, including leadership of U.S. commercial operations at Seagen where he oversaw ADCETRIS, PADCEV, TUKYSA and TIVDAK, and senior sales roles at Genentech managing AVASTIN, RITUXAN and XOLAIR.
3. Implications for Gedatolisib
His proven success in launching oncology drugs is intended to guide Celcuity’s preparations for the potential approval and market introduction of gedatolisib in breast cancer later this year.